A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Gliomas
A study for patients with malignant glioblastoma or glioma using study drug PF-06840003
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR0112
U.S. Govt. ID: NCT02764151
Contact: Andrew Lassman: 212-342-0571 / abl7@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to learn about the effects of the study drug, PF-06840003,and to find the best dose for treating research subjects/participants with malignant glioblastoma or anaplastic glioma. PF-068400003 is a new investigational drug. A new investigational drug is one that is currently not approved for sale in this country. PF-06840003 is a type of therapy called an IDO1 inhibitor. Indoleamine-pyrrole 2,3 dioxygenase, or IDO1, is an enzyme that is encoded by the IDO1 gene. It has been shown that IDO1 allows tumor cells to escape from your immune system which allows the tumor cells to remain in your body and grow. The study will see if PF-06840003 is able to change the ways that your tumor cells escape from your immune system. This research study will be the first time PF-06840003 will be given to humans. The optimal dose of PF-06840003 to be used to treat research subjects/participants is unknown.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Have you been diagnosed with glioblastoma or glioma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Andrew Lassman